Journals / Türk Hematoloji Onkoloji Dergisi / 2002 / Cilt: 12 - Sayı: 4

Evaluation of early and response in locally advanced non-small cell lung cancer treated with accelerated concomitant boost radiotherapy

Lokal ileri küçük hücreli dışı akciğer kanserinin akselere konkomitant boost radyoterapi ile tedavisinde erken toksisite ve cevap değerlendirilmesi

Pages
196–200
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In conclusion, it was thought that therapy schedule of accelerated concomitant boost radiotherapy is applicable with acceptable toxicities and improved response rates.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Poor results obtained with conventional radiotherapy in the treatment of non-small cell lung cancer have revived treatment with different fractionations.
📊
Key Findings & Data:In our clinic concomitant boost radiotherapy was applied to 30 patients between June 2000 and December 2001 in two arms namely with Co-60 and linear accelerator.
💡
Conclusion & Impact:In conclusion, it was thought that therapy schedule of accelerated concomitant boost radiotherapy is applicable with acceptable toxicities and improved response rates.
🔬Design:Research Article
📍Scope:2000 Verileri
⚙️Variables:Tedavi sonucu · Karsinom · küçük hücreli dışı akciğer

Abstract

Poor results obtained with conventional radiotherapy in the treatment of non-small cell lung cancer have revived treatment with different fractionations. In our clinic concomitant boost radiotherapy was applied to 30 patients between June 2000 and December 2001 in two arms namely with Co-60 and linear accelerator. Therapy was completed after total 63 Gy dose (180 cGy for 35 fractions) administered within 5 weeks. After completion of the therapy 26 patients were evaluated. They were assessed with respect to acute side effects, dermal, esophageal and lung toxicities. Among patients treated with Co-60, grade 3-4 toxicity was not seen except one patient with grade 3 dermal toxicity. Only acute dermal reactions were statistically significant in patients treated with Co-60 in comparison with the group treated with linear accelerator (p=0.012). Complete and partial radiological response rates were determined to be 7.6% and 50% respectively. In conclusion, it was thought that therapy schedule of accelerated concomitant boost radiotherapy is applicable with acceptable toxicities and improved response rates.

Özet

İnoperabl küçük hücreli dışı akciğer kanserinin konvansiyonel radyoterapi ile elde edilen tedavi sonuçlarının kötü olması farklı fraksiyonasyon şekilleriyle tedaviyi gündeme getirmiştir. Kliniğimizde Haziran 2000-Aralık 2001 tarihlerinde 30 hastaya konkomitant boost radyoterapi ile iki kolda, Co-60 ve linear akseleratörle tedavi uygulandı. Toplam 63 Gy doz (180 cGy/35 fx) uygulanarak tedavi 5 haftada tamamlandı. Tedavi sonunda 26 hasta değerlendirmeye alındı. Akut yan etkiler; cilt, özefagus ve akciğer toksisiteleri açısından değerlendirildi. Co-60 ile tedavi edilen l hastada grade 3 cilt toksisitesi haricinde başka hiçbir hastada grade 3-4 toksisite görülmedi. Sadece akut cilt reaksiyonları Co-60 ile tedaviye alman hasta grubunda linear akseleratörle tedavi edilen gruba göre istatistiksel olarak anlamlı bulundu (p=0.012). Radyolojik tam cevap oranı %7.6, parsiyel cevap oranı ise %50 olarak belirlendi. Sonuç olarak akselere konkomitant boostlu RT şemasının uygulanabilir ve akut toksisitenin kabul edilebilir olduğu ve iyi cevap oranları elde edildiği düşünüldü.

🔖

Cite This Article

İZMİRLİ, M., YAMAN, F., BÜYÜKPOLAT, Y., YÖNEY, A., ÜNSAL, M. (2002). Evaluation of early and response in locally advanced non-small cell lung cancer treated with accelerated concomitant boost radiotherapy. Türk Hematoloji Onkoloji Dergisi, Cilt: 12 - Sayı: 4, 196–200. https://ajindex.com/articles/418733

References (13)

  1. Lee BJS, Scott C, Komaki R, et al. Concurrent chemoradiation for locally advanced inopera'bl NSCLC: Radiation Therapy Oncology Group protocol 91-6. (RTOG 91-06). J Clin Oncol 14(4): 1055-1064,1996
  2. Fu X, Jiang G, Wang L, et al. Hyperfractionated accelerated radiatin therapy for NSCLC:Clinical phase I-II trial. Int J Radiat Oncol Biol Phys 39 (3):545-552,1997
  3. Emami B, Perez CA, Graham MV, Lung. In:Principles and practice of radiation oncology. Peraz CA, Brady LW, (eds). 3rd ed. Philadel¬ phia, J.B. Lippincott Company, 1998:1181- 1221
  4. Perez CA, B auer M, Edelstein S, et al. Impact of tumor control on carcinoma of lung treated with irradiation. Int J Radiat Oncol Biol Phys 12:539-547,1986
  5. Morgan GW, Pharm B, Breit SN, et al. Radiation and the lung: A revaluation of mechanisms mediating pulmonary injury. Int J Radiat Oncol Biol Phys 31(2):361-369, 1995
  6. King SC, Acker JC, Kussin PS, et al. High-dose, hyperfractionated, accelerated radiotherapy using a concurrent boost for the treatment of NSCLC; unusual toxicity and promising early results. Int J Radiat Oncol Biol Phys 36(3):599-599,1996
  7. Fowler JF, The linear-quadratic formula and progres in fractionated radiotherapy. Br J Radiol 62:679-694, 1989
  8. Graham MV, Pajak TE, Emami B, et al. Phase I- II study of locally advanced (T3-4) non-oat cell lung cancer with concomitant boost radiotherapy by the radiation therapy oncology group (RTOG 83-12) long term results. Int J Radiat Oncol Biol Phys 31: 819-825, 1995
  9. Ginsberg RJ, Kris MG, Armstrong JG, Nonsmall cell lung cancer. In:Cancer, principles and practice of oncology. De Vita VT, Hellman S, Rosenberg SA,(eds). 4th ed. Philadelphia, J.B. Lippincott Company, 1993: 673-722 10. Fowler JF, Fractionation. and therapeutic gain. In:The biological basis of radiotherapy. Steel GG, Adams GE, Horwich A, (eds) 2nd ed. Amsterdam, Oxford, Elsevier science publishers BV, 1989:181-207
  10. Hall EJ, Time, dose and fractionation in radio¬ therapy, In: Radiobology for the radiologist, Hall EJ, (ed). Philadelphia, J.B. Lippincott Company, 1988: 239-259
  11. Yu E, Souhami L, Guerro J, et al. Accelerated fractionation in inoperable non-small cell lung cancer. Cancer 71:2727-2731,1993
  12. Kerr KM, Lamb D, Actual growth rate and tumor cell proliferation in human pulmonary neoplasms. Br J Cancer 50: 343-349,1984
  13. Byhardt RW, Pajak TF, Emami B, et al. A phase I-II study to evaluate accelerated fractionation via concomitant boost for squamous, adeno and la